Regimen patients receive oral imatinib mesylate. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy8

K562 Cells Philadelphia Chromosome Cell Line, Tumor Chromosomes, Human, Pair 9 Neoplastic Stem Cells Myeloid Progenitor Cells Bone Marrow Cells, Cultured

Diseases25

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Leukemia, Myeloid, Chronic-Phase Blast Crisis Hypereosinophilic Syndrome Hypopigmentation Gastrointestinal Neoplasms Philadelphia Chromosome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Dermatofibrosarcoma Mastocytosis, Systemic Fibromatosis, Aggressive Leukemia, Myeloid, Accelerated Phase Lichenoid Eruptions Neoplasm, Residual Recurrence Disease Progression Primary Myelofibrosis Precursor Cell Lymphoblastic Leukemia-Lymphoma Scleroderma, Systemic Histiocytoma, Malignant Fibrous Fibrosis Graves Ophthalmopathy Neutropenia Leukemia

Chemicals and Drugs34

Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Receptor, Platelet-Derived Growth Factor beta Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Receptors, Platelet-Derived Growth Factor Enzyme Inhibitors Pregnatrienes Thiazoles Proto-Oncogene Proteins c-sis Harringtonines Interferon-alpha mRNA Cleavage and Polyadenylation Factors Ketones Rifabutin Pyrroles Furans Hydroxyurea STAT5 Transcription Factor Platelet-Derived Growth Factor Cytarabine Stem Cell Factor RNA, Messenger Indoles Oncogene Proteins, Fusion Antigens, CD34 Bleomycin Milk Proteins

Analytical, Diagnostic and Therapeutic Techniques and Equipment25

Cytogenetic Analysis Treatment Outcome Remission Induction Drug Approval Drug Administration Schedule Disease-Free Survival Antineoplastic Combined Chemotherapy Protocols Administration, Oral Survival Analysis Treatment Failure Salvage Therapy Prognosis Survival Rate Combined Modality Therapy Follow-Up Studies In Situ Hybridization, Fluorescence Reverse Transcriptase Polymerase Chain Reaction Neoadjuvant Therapy Inhibitory Concentration 50 Transplantation, Homologous Hematopoietic Stem Cell Transplantation Blood Cell Count Immunohistochemistry Clinical Trials as Topic Drug Therapy, Combination

Phenomena and Processes16

Drug Resistance, Neoplasm Genes, abl Philadelphia Chromosome Dose-Response Relationship, Drug Time Factors Apoptosis Cell Proliferation Drug Synergism Phosphorylation Mutation Gene Expression Regulation, Leukemic Chromosomes, Human, Pair 9 Inhibitory Concentration 50 Signal Transduction Blood Cell Count Cell Survival

Disciplines and Occupations2

Cytogenetics Immunohistochemistry

Anthropology, Education, Sociology and Social Phenomena2

Drug Approval United States Food and Drug Administration

Technology, Industry, Agriculture1

Information Science1

Health Care8

Treatment Outcome Disease-Free Survival Survival Analysis Treatment Failure Survival Rate United States Food and Drug Administration Follow-Up Studies Clinical Trials as Topic

Anatomy Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Information Science Health Care

Benzamides Piperazines Pyrimidines Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Leukemia, Myeloid, Chronic-Phase Receptor, Platelet-Derived Growth Factor beta Drug Resistance, Neoplasm Blast Crisis Genes, abl Hypereosinophilic Syndrome Cytogenetic Analysis Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Hypopigmentation K562 Cells Gastrointestinal Neoplasms Treatment Outcome Philadelphia Chromosome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Remission Induction Receptors, Platelet-Derived Growth Factor Dermatofibrosarcoma Mastocytosis, Systemic Dose-Response Relationship, Drug Drug Approval Enzyme Inhibitors Drug Administration Schedule Disease-Free Survival Antineoplastic Combined Chemotherapy Protocols Pregnatrienes Cell Line, Tumor Thiazoles Fibromatosis, Aggressive Proto-Oncogene Proteins c-sis Administration, Oral Harringtonines Leukemia, Myeloid, Accelerated Phase Time Factors Apoptosis Survival Analysis Interferon-alpha Cell Proliferation Lichenoid Eruptions Treatment Failure Drug Synergism Salvage Therapy mRNA Cleavage and Polyadenylation Factors Neoplasm, Residual Prognosis Phosphorylation Survival Rate Mutation Recurrence Ketones Disease Progression Rifabutin Pyrroles Cytogenetics Furans Gene Expression Regulation, Leukemic Combined Modality Therapy United States Food and Drug Administration Follow-Up Studies Primary Myelofibrosis Precursor Cell Lymphoblastic Leukemia-Lymphoma Hydroxyurea In Situ Hybridization, Fluorescence Chromosomes, Human, Pair 9 Reverse Transcriptase Polymerase Chain Reaction Neoplastic Stem Cells STAT5 Transcription Factor Platelet-Derived Growth Factor Cytarabine Scleroderma, Systemic Neoadjuvant Therapy Inhibitory Concentration 50 Transplantation, Homologous Stem Cell Factor Histiocytoma, Malignant Fibrous Signal Transduction RNA, Messenger Indoles Myeloid Progenitor Cells Hematopoietic Stem Cell Transplantation Blood Cell Count Fibrosis Cell Survival Immunohistochemistry Graves Ophthalmopathy Oncogene Proteins, Fusion Antigens, CD34 Bleomycin Clinical Trials as Topic Bone Marrow

No FAQ available that match "regimen patients receive oral imatinib mesylate"